4DMT reports Q2 net loss $29.6M; cash $310M; positive interim data for 4D-150 and 4D-710; Astellas deal

4D Molecular Therapeutics, Inc.

2023-Q2 EPS reported -$1.63 revenue$538,000

Q2 net loss $29.6M ($28.1M prior year); R&D expense $23.6M; cash $310M as of June 30, 2023.
Cash includes $129M net public offering proceeds and $20M Astellas upfront; expected to fund into H1 2026.
Positive interim 4D-150 data: 100% reduction in anti-VEGF injections at high dose; durable response >1 year.
Phase 2 Dose Expansion of 4D-150 completed enrollment of 50 patients nearly two quarters ahead of schedule.
License with Astellas: $20M upfront, up to $942.5M milestones plus royalties for R100 vector in rare ophthalmic diseases.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

4D Molecular Therapeutics, Inc. reported financial results for three months ended June 30, 2023.

Period: three months ended June 30, 2023
Result: reported results

Exact text from the filing

On August 9, 2023, 4D Molecular Therapeutics, Inc. (“4DMT”) announced its financial results for the three months ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

4D Molecular Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-040653

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.